Global Pharyngitis Treatment Market - 2023-2030

Market Overview

Global Pharyngitis Treatment Market reached US$ 2.3 billion in 2022 and is expected to reach US$ 3.2 billion by 2030, growing with a CAGR of 4.5% during the forecast period 2023-2030.

The global pharyngitis treatment market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics such as increasing prevalence, increasing demand for novel therapeutics, rising clinical trials, and others. Government investments in novel treatment procedures will continue to drive and boost the global market. The global pharyngitis treatment industry is placing increasing emphasis to reduce its impact.

Pharyngitis also known as sore throat, has two types acute pharyngitis and chronic pharyngitis. The treatment is based on the type and severity of the disease. Many drugs such as antibiotics, NSAIDs, antifungal drugs, antiviral drugs, corticosteroids, antitussives, and others are used in the treatment of sore throat. But antibiotics are considered first-line treatment drugs. Similarly, North America dominates the global market by capturing the largest market share owing to the advanced healthcare infrastructure and presence of major players.

Owing to the increasing prevalence of pharyngitis or sore throat, growing awareness, increasing demand for novel therapeutics, rising clinical trials, increasing adoption of personalized medicines, increasing demand for Over-the-Counter (OTC) medicines, and advancements in treatment options are the major factors expected to drive market over the forecast period.

Market Dynamics

Increasing Demand for Novel Therapeutics is Expected to Drive the Growth of the Pharyngitis Treatment Market

There is an increasing demand for novel therapeutics, which is expected to drive the global market over the forecast period. The currently available pharyngitis treatments and therapeutics are the most widely used, especially antibiotics, but there are also some side effects associated with these drugs. Novel therapeutics are continuously evolving with better patient outcomes, and there is continuously increasing demand for innovative products which have minimal side effects.

For instance, on May 16, 2022, Vicks announced the launch of Vicks Tulsi cough drops in India. By adding Tulsi flavor to its range of products, the brand reaffirms its aim of making traditional remedies, passed down by generations, convenient and accessible to all with very less side effects compared to other medications.

Moreover, the ongoing research activities on pharyngitis therapeutics enhance the opportunities for better treatment, and the development of innovative treatment approaches has led to the discovery of potential novel therapeutic options which are very suitable for all ages including kids. These advancements increase the way for the introduction of novel drugs with different mechanisms of action.

For instance, on February 11, 2021, Honibe announced the launch of HoneyPops, the first (up to) 99% pure honey lollipop for kids that soothes sore throats naturally. HoneyPops are manufactured in Prince Edward Island, Canada, using up to four all-natural ingredients including Canadian honey, menthol, natural flavor, and natural color. They have no added sugar and are available in kid-friendly cherry, strawberry, lemon, and natural honey.

Increasing Demand for OTC Medicines Expected to Drive the Growth of the Pharyngitis Treatment Market

There is an increasing demand for OTC medications which is expected to drive the market over the forecast period. OTC medications for pharyngitis, such as throat lozenges, sprays, different types of drugs, and pain relievers, are readily available in the hospital, online and retail pharmacies, supermarkets, and convenience stores. Patients can purchase OTC products without a prescription or a visit to a hospital or clinic, making them convenient for immediate symptom relief.

For instance, on November 1, 2021, Mucinex, the trusted OTC cough and cold brand announced the launch of Mucinex InstaSoothe, a new product line inclusive of lozenges and spray designed to numb, soothe, and relieve sore throat pain. The new products include Mucinex InstaSoothe Sore Throat + Soothing Comfort Lozenges, Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges, and Mucinex InstaSoothe Sore Throat + Pain Relief Spray.

Moreover, OTC medications have the ability to provide rapid relief for common symptoms like irritation, discomfort, and sore throat which are associated with pharyngitis. This quick relief can be particularly appealing to individuals looking for immediate symptom management. Their wide availability without prescription is also a major factor for OTC medicines.

Severe Side Effects Associated with Antibiotics Will Hamper the Market's Growth

There are moderate to severe side effects associated with the antibiotics, which are expected to hamper the market growth over the forecast period. Side effects such as diarrhea, rashes, dizziness, and other adverse effects are most commonly seen in patients who are using more antibiotics. And the side effects caused by the antibiotics may last up to 2 months, which may cause other types of infections.

Furthermore, antibiotics, like all medications, can cause adverse reactions and side effects. These can range from mild gastrointestinal disturbances to more serious allergic reactions, which can deter individuals from using antibiotics and seeking treatment. Antibiotics can also increase the risk of secondary infections such as yeast infections or other opportunistic infections due to the disruption of the body's normal microbial flora.

The Availability of Alternative Treatment Options Will Also be Expected to Hamper the Market Growth

The availability of alternative treatment options is expected to hamper the market growth over the forecast period. Many individuals with pharyngitis are focussing on natural remedies such as honey, ginger, herbal products like herbal tea, and other essential oils to avoid the adverse effects of the drugs, which in turn hamper the market growth.

Additionally, many patients are focussing on and adopting dietary substances like vitamin C-rich fruits, avoiding spicy food, and consuming more fluids instead of using pharmaceutical therapeutics to skip the moderate to severe side effects associated with pharmaceutical drugs. This may helps to reduce the sore throat with lesser or no side effects.

Segment Analysis

The global pharyngitis treatment market is segmented based on disease type, drug class, distribution channel and region.

The Antibiotics Segment Accounted for Approximately 36.8% of the Market Share

Antibiotics are expected to hold the largest market share over the forecast period owing to their wide availability and acceptability. Antibiotics have the ability to provide rapid relief from pharyngitis symptoms by targeting the underlying infection, and results in quick and rapid relief from sore throat, penicillin and its derivatives, such as amoxicillin, are often prescribed as the first-line antibiotics. This can be especially important for individuals who have severe symptoms or those who need to recover quickly.

Moreover, antibiotics are more commonly used for the treatment of pharyngitis, especially when the condition is caused by bacterial infections, such as streptococcal bacteria. Group A Streptococcus (Streptococcus pyogenes) is a common bacterial pathogen that causes streptococcal pharyngitis, also known as strep throat (type of pharyngitis). Antibiotics are effective in treating bacterial infections and can help alleviate symptoms, prevent complications, and reduce the spread of infection to others.

For instance, according to the Centers for Disease Control and Prevention, Penicillin or amoxicillin is the antibiotic of choice to treat group A strep pharyngitis. However, resistance to azithromycin and clarithromycin is common in some communities. For patients with a penicillin allergy, recommended regimens include narrow-spectrum cephalosporins (cephalexin, cefadroxil), clindamycin, azithromycin, and clarithromycin.

Geographical Penetration

North America Accounted for Approximately 37.7% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Favourable Reimbursement Policies

North America is expected to hold the largest market share over the forecast period owing to the advanced healthcare infrastructure and favorable reimbursement policies. North America especially the United States and Canada is known for its advanced and well-established healthcare infrastructure including hospitals, specialty clinics, ENT clinics, and others which offers better treatment and therapeutics for fast and quick relief from pharyngitis.

Moreover, due to the region's high population, there is a high prevalence of pharyngitis, this increased prevalence increases the demand for novel therapeutics. North America offers favorable reimbursement policies for these novel therapeutics enhancing improved patient outcomes. This improved insurance coverage and reimbursement policies offers the better treatment for many patients at affordable costs, leading to market dominance in the region.

Competitive Landscape

The major global players in the pharyngitis treatment market include Pfizer Inc., Novartis, Amneal Pharmaceuticals LLC, Kenvue Inc., Thornton & Ross Ltd, Reckitt Benckiser Group Plc, Honibe, Prestige Consumer Healthcare Inc., Traditional Medicinals, Inc., and Lozen Pharma Pvt. Ltd among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global pharyngitis treatment market. During the pandemic, regulatory approvals for innovative treatments for pharyngitis treatment have been temporarily postponed due to the redirected focus towards the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations of pharyngitis patients due to the similar symptoms associated with COVID-19. Many hospitals are focused on COVID-19 cases, due to the similar symptom, and the focus on sore throat has increased to reduce the severity.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as antibiotics and other drugs. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks. Furthermore, telemedicine is a positive approach resulted from the COVID-19 pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global pharyngitis treatment market. The conflict has less impact on the market mainly due to the low prevalence and absence of key market players in this region and the impact of the import and export of raw materials such as different types of drugs.

By Disease Type

• Acute Pharyngitis
• Chronic Pharyngitis

By Drug Class

• Antibiotics
• Antiviral Drugs
• Corticosteroids
• Antifungals
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On May 25, 2023, Traditional Medicinals, a leading botanical wellness company with more than 60 high-quality teas, lozenges, and capsules, announced a partnership with Dave Matthews Band through sponsorship of REVERB's Eco-Village during the band's U.S. summer concert tour. Dave Matthews has been using Throat Coat tea for years, as part of his throat care routine before performing and while onstage sharing his music with fans. Through his connection to the Throat Coat brand and REVERB's mission to empower the music community to take meaningful environmental action, Traditional Medicinals saw a values-aligned opportunity to connect people, plants, and the planet through this partnership.
• On January 10, 2022, Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial-1 which compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19 and their related diseases including sore throat, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefits over placebo.

DataM Intelligence Opinion:

According to the DataM Intelligence, the pharyngitis treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence, increasing adoption of natural therapeutics, increasing adoption of OTC medicines, and their wide availability. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many research activities are still going on for novel therapeutics for quick relief from sore throat, which is expected to growth of the global pharyngitis treatment market in the upcoming years.

Why Purchase the Report?

• To visualize the global pharyngitis treatment market segmentation based on disease type, drug class, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pharyngitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pharyngitis treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies